Cambodia Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Cambodia Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Cambodia Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: Cambodia is increasingly looking to provide greater health coverage for its population and this bodes well for pharmaceutical firms over the longer term . However, consistently low levels of government health expenditure mean that there has been, and will continue to be, a lack of healthcare resources available for the development of the sector. Until the government shows more concrete commitment towards the sector, progress of healthcare provision to the population will be hindered .

Headline Expenditure Projections

  • Pharmaceuticals: KHR1,008.1bn (USD250mn) in 2015 to KHR1,113.5bn (USD280mn) in 2016; +10.5% in local currency terms and US dollar terms. Forecast remains unchanged from previous quarter.

  • Healthcare: KHR3,981.1bn (USD1.0bn) in 2015 to KHR4,181.1bn (USD1.1bn) in 2016; +5.0% in local currency terms and US dollar terms. Forecast remains unchanged from previous quarter .

Headline Pharmaceuticals & Healthcare Forecasts (Cambodia 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
e/f = BMI estimate/forecast. Source: National Sources, BMI
Pharmaceutical sales, USDbn 0.230 0.250 0.280 0.310 0.340 0.370 0.410
Pharmaceutical sales, % of GDP 1.36 1.38 1.38 1.38 1.38 1.37 1.36
Pharmaceutical sales, % of health expenditure 24.0 25.3 26.6 27.9 29.3 30.5 31.8
Health spending, USDbn 0.950 1.000 1.050 1.100 1.150 1.210 1.280

Risk/Reward Index

Cambodia's Pharmaceutical Risk/Reward Index score for Q316 is 32.9 out of the maximum 100. The country scored below average for almost all indicators and sub-indicators including overall market expenditure, sector value growth and pensionable population. Consequently, with this low score, Cambodia ranks second-to-last out of the 19 key markets in the Asia Pacific region, ahead of Myanmar. Cambodia mainly suffers from low per capita consumption, stemming from low wages, the absence of a national health insurance scheme and the wider lack of government financing in the country, poor intellectual property protection and cumbersome bureaucracy.

Latest Updates

  • In April 2016, the World Bank stated that 100% of Cambodia's poor are covered by the Health Equity Fund and that more babies are being delivered by health professionals in the country.

  • In the same month, according to local media outlet The Phnom Penh Post, approximately 360,000 workers in various parts of the country will get access to healthcare coverage from May 1 due to the expansion of the National Social Security Fund.

  • In March 2016, CEO of GlaxoSmithKline, Sir Andrew Witty announced that the company would not file for patents for new medicines in poor countries such as Cambodia.

BMI Economic View

Cambodia is currently undergoing a sharp slowdown in tourist arrival growth, which threatens to undermine the country's robust economic growth rate. The ongoing deterioration in domestic political stability poses an additional risk, given the recent murder of prominent government critic Kem Ley.

BMI Political View

The Cambodian government's latest crackdown on the opposition ahead of the 2017 elections reflects growing concerns among the ruling Cambodian People's Party over a loss of electoral support and could trigger a rise in protests from the opposition and garment worker unions. We have downgraded Cambodia's short-term political risk index to 62.1 out of 100 from 62.7 previously, owing to a decline in the social stability score to 55.0 from 57.5.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Cambodia 2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Cambodia 2012-2020)
12
Healthcare Market Forecast
12
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2012-2020)
14
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2012-2020)
15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2012-2020)
15
Pharmaceutical Trade Forecast
16
Table: Pharmaceutical Trade Data And Forecasts (Cambodia 2014-2020)
17
Industry Risk/Reward Index
18
Asia Pacific Risk/Reward Index
18
Cambodia Risk/Reward Index
24
Rewards
24
Risks
24
Market Overview
26
Healthcare Sector
26
Health Insurance
28
Research & Development
29
Clinical Trials
30
Epidemiology
31
Regulatory Review
34
Regulatory Regime
34
Intellectual Property Issues
34
Counterfeit Medicines
35
Pricing And Reimbursement
36
Competitive Landscape
37
Pharmaceutical Sector
37
Table: Multinational Market Activity
39
Wholesale Sector
40
Company Profile
42
Pfizer
42
PharmaProduct Manufacturing (PPM)
44
Sanofi
47
Demographic Forecast
50
Table: Population Headline Indicators (Cambodia 1990-2025)
51
Table: Key Population Ratios (Cambodia 1990-2025)
51
Table: Urban/Rural Population & Life Expectancy (Cambodia 1990-2025)
52
Table: Population By Age Group (Cambodia 1990-2025)
52
Table: Population By Age Group % (Cambodia 1990-2025)
53
Demographic Forecast
55
Table: Population Headline Indicators (Laos 1990-2025)
56
Table: Key Population Ratios (Laos 1990-2025)
56
Table: Urban/Rural Population & Life Expectancy (Laos 1990-2025)
57
Table: Population By Age Group (Laos 1990-2025)
57
Table: Population By Age Group % (Laos 1990-2025)
58
Demographic Forecast
60
Table: Population Headline Indicators (Myanmar 1990-2025)
61
Table: Key Population Ratios (Myanmar 1990-2025)
61
Table: Urban/Rural Population & Life Expectancy (Myanmar 1990-2025)
62
Table: Population By Age Group (Myanmar 1990-2025)
62
Table: Population By Age Group % (Myanmar 1990-2025)
63
Glossary
65
Methodology
67
Pharmaceutical Expenditure Forecast Model
67
Healthcare Expenditure Forecast Model
67
Notes On Methodology
68
Risk/Reward Index Methodology
69
Index Overview
70
Table: Pharmaceutical Risk/Reward Index Indicators
70
Indicator Weightings
71

The Cambodia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Cambodia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Cambodia pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Cambodia, to test other views - a key input for successful budgeting and strategic business planning in the Cambodian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Cambodian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Cambodia.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.